Global recession tightens grip on cancer services and research spending

February 28, 2009

Reduced access to expensive cancer treatments; reduced investment in drug discovery; and less support for cancer sufferers and survivors could all be on the horizon in continental Europe and in the UK, as the global financial crisis continues to squeeze the budgets of governments, companies, and private individuals. These are the conclusions of a series of inter-related reports published in the March issue of The Lancet Oncology.

The reports also discuss how the patchy provision of screening programmes and unequal spending on cancer care within Europe and the UK, mean the blow to cancer-care provision inflicted by the economic downturn will be felt more keenly in some areas than in others.

In the first of two Special Reports, The Lancet Oncology highlights disparities in access to cancer services across Europe, and finds equal access to novel cancer drugs is a long way off. As Nils Wilking (Karolinska Institute, Sweden), co-author of the Comparator Report on Patient Access to Cancer Drugs in Europe, points out: "Per capita spending on drugs (new as well as pre-1999) is significantly lower in the UK compared with France and almost all other western European countries".

The deepening economic crisis looks set to reduce this spending further. Commenting in the second Special Report, Nick Bosanquet (Imperial College, London, UK) says: "In Europe there are likely to be informal steps towards rationing access to new treatments as governments seek to contain spending; we are already seeing this in the UK through the restrictions placed on the uptake of expensive drugs by the National Institute for Health and Clinical Excellence (NICE)." Additionally, Alan Maynard (University of York, UK) emphasises the UK Institute of Fiscal Studies has estimated NHS funding may equate to zero real growth for the 3 years after 2010. Reflecting on the rest of Europe, Maynard also adds: "In Europe some will fare better but some will fare worse, notably Ireland and the Baltic republics."

Programmes of cancer support and research that rely on charitable funding are also likely to feel the squeeze, with rising unemployment and falling sales and profits conspiring to reduce donations by companies and private individuals. Cancer Research UK is forecasting a 4��% drop in income in 2009 compared with 2008, and Macmillan Cancer Support predicts that the recession will be especially hard on people affected by cancer who rely on them for financial support.

As purse strings tighten across the board, so the need becomes more pressing for efficient administration and an equitable distribution of cancer services. A situation far removed from the current inequalities and waste highlighted by The Lancet Oncology in this month's editorial, the Leading Edge.

Commenting on the widening inequalities in access to cancer treatments across the UK, The Lancet Oncology says: "This makes a mockery of the concept of a 'National' Health Service, when the four countries within the UK each have different interpretations...In the current global recession, a root and branch re-evaluation of services, focused on patient-centred medicine...would undoubtedly improve care for patients with cancer; reduce polarisation in accessibility; and possibly even shrink healthcare budgets".
-end-
For Leading Edge and Features see: http://press.thelancet.com/RecessionEurope.pdf

Lancet

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.